Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of SSGJ-610 in Severe Eosinophilic Asthma
NCT05584306Phase 1Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Dec 2021
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 610 in eosinophilic asthma (EA) (4 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoint: Adverse events (AEs). Status: unknown.
02
Drugs
610
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT05584306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584306.